SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study
暂无分享,去创建一个
J. Pawlotsky | L. Landraud | É. Azoulay | E. Audureau | R. Clere-Jehl | D. Descamps | A. Roque-Afonso | M. Chaix | D. Roux | N. de Prost | T. Pham | J. Mayaux | S. Fourati | L. Morand‐Joubert | C. Luyt | B. Visseaux | C. Rodriguez | A. Marcelin | A. Mekontso Dessap | M. Salmona | S. Gaudry | G. Voiriot | S. Marot | T. Urbina | C. Dubois | S. Brichler | Zakaria Ait Hamou | A. L’Honneur | R. Arrestier | R. Bellaiche
[1] Z. Mo,et al. Emerging Severe Acute Respiratory Syndrome Coronavirus 2 Mutation Hotspots Associated With Clinical Outcomes and Transmission , 2021, Frontiers in Microbiology.
[2] K. Bhaskaran,et al. Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Sergei L. Kosakovsky Pond,et al. The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages , 2021, Cell.
[4] P. Meredith,et al. The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out , 2021, The Lancet Infectious Diseases.
[5] P. Horby,et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study , 2021, The Lancet Infectious Diseases.
[6] L. Hennighausen,et al. Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation , 2021, medRxiv.
[7] P. Maes,et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters , 2021, EBioMedicine.
[8] M. Singer,et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study , 2021, The Lancet Infectious Diseases.
[9] J. Mossong,et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[10] N. G. Davies,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[11] Sougata Niyogi,et al. ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection , 2020, Epidemiology and Infection.
[12] S. Pongor,et al. Different mutations in SARS-CoV-2 associate with severe and mild outcome , 2020, International Journal of Antimicrobial Agents.
[13] Sebastian Maurer-Stroh,et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study , 2020, The Lancet.
[14] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[15] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[16] Arthur S Slutsky,et al. Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .
[17] I. McDowell,et al. A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.
[18] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[19] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[20] S. Lemeshow,et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.